Chris Peetz, Mirum Pharma CEO
Mirum discontinues PhIIb 'Ohana' study in pregnancy setting
One of Mirum Pharmaceuticals’ three attempts to turn around an axed Shire NASH drug has ended.
The biotech put out word it will cull a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
